Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SULFINPYRAZONE vs BENEMID
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Competitive inhibitor of tubular organic anion transport, increasing uric acid excretion; also inhibits platelet aggregation.
Competitive inhibitor of renal tubular secretion of organic acids (urate, penicillin, other drugs), enhancing urate excretion and reducing serum uric acid levels. Also inhibits renal transport of weak organic acids.
Chronic gouty arthritis,Hyperuricemia,Off-label: Prevention of gout flares during initiation of allopurinol
Treatment of hyperuricemia associated with gout and gouty arthritis,Adjunctive therapy for penicillin and cephalosporin antibiotics to prolong their serum half-life
100-200 mg orally twice daily, initially, then increase to 200-400 mg twice daily.
250 mg orally twice daily for 1 week, then 500 mg orally twice daily; maximum 2 g/day.
2-5 hours (terminal elimination half-life; prolonged in renal impairment to up to 10 hours)
Terminal elimination half-life 6-12 hours in adults; prolonged to 12-24 hours in renal impairment or elderly; clinically significant for twice-daily dosing
Primarily hepatic via oxidation and conjugation; major metabolite is sulfinpyrazone sulfide.
Hepatic metabolism via oxidation and glucuronidation; minimal CYP450 involvement.
Renal: ~90% (50% unchanged, 50% as glucuronide and other metabolites); Biliary/fecal: ~10%
Renal (70-80% as unchanged drug and metabolites), biliary/fecal (20-30%)
98-99% (primarily to albumin)
Approximately 85-95% bound primarily to albumin
0.15-0.25 L/kg (low Vd, consistent with high protein binding and limited tissue distribution)
0.15-0.30 L/kg; indicates limited extravascular distribution, consistent with high protein binding and renal elimination
Oral: 80-90% (well absorbed; decreased with food)
Oral: >90%
GFR >50 m L/min: no adjustment. GFR 10-50 m L/min: reduce dose by 50%. GFR <10 m L/min: avoid use.
Cr Cl <50 m L/min: avoid use; Cr Cl 50-90 m L/min: reduce dose by 50%.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50%. Child-Pugh C: avoid use.
No specific guidelines; use with caution in severe hepatic impairment.
Safety and efficacy not established; use not recommended.
Not recommended for children under 2 years. For older children: 25 mg/kg/day divided every 6 hours, up to 40 mg/kg/day maximum 2 g/day.
Start at lower end of dosing range (100-200 mg daily) and titrate cautiously due to increased risk of renal impairment and drug interactions.
Start at low end of dosing range (250 mg twice daily); monitor renal function and urate levels.
None.
No FDA black box warning.
Risk of acute gouty attacks during initial therapy,Uricosuric effect may lead to urolithiasis; maintain adequate hydration and urine alkalinization,Possible cross-allergenicity with sulfonamides,Monitor renal function and complete blood counts
Risk of acute gouty arthritis upon initiation; use NSAIDs or colchicine prophylactically. Use with caution in patients with peptic ulcer disease, renal impairment (Cr Cl <50 m L/min), or history of uric acid calculi. May cause aplastic anemia and other blood dyscrasias. Avoid use during acute gout attack.
Active peptic ulcer disease,Known hypersensitivity to sulfinpyrazone or sulfonamides,Severe hepatic or renal impairment
Known hypersensitivity to probenecid; use with methotrexate or other nephrotoxic agents; severe renal impairment (Cr Cl <50 m L/min); blood dyscrasias; uric acid kidney stones; children under 2 years of age.
Avoid high-purine foods (e.g., organ meats, anchovies, sardines, beer) as they may reduce efficacy. Maintain adequate hydration; alcohol consumption should be minimized as it can increase uric acid levels.
Avoid high doses of aspirin or salicylate-containing foods. Maintain adequate fluid intake. No specific food restrictions but alcohol may increase serum uric acid and reduce efficacy. Avoid large doses of vitamin C (may acidify urine and increase urate stone risk).
Sulfinpyrazone is contraindicated in pregnancy. Animal studies have shown teratogenic effects, and there are no adequate human studies. First trimester exposure may carry a risk of congenital malformations. Second and third trimester use may cause adverse fetal effects including premature closure of the ductus arteriosus, oligohydramnios, and renal dysfunction.
FDA Pregnancy Category D for second and third trimesters due to risk of neonatal hemolysis and jaundice from sulfonamide component; first trimester use associated with possible neural tube defects based on animal data and limited human reports.
Sulfinpyrazone is excreted into breast milk in small amounts. The M/P ratio is unknown. Due to the risk of serious adverse reactions in nursing infants, including the potential for kernicterus in jaundiced infants, use during breastfeeding is not recommended.
Small amounts of probenecid and sulfonamide excreted into breast milk; M/P ratio not established. Potential for hemolysis in G6PD-deficient infants, jaundice, and kernicterus in premature infants. Contraindicated in nursing mothers due to sulfonamide component.
No specific dose adjustments have been established. Due to increased renal blood flow and glomerular filtration rate during pregnancy, pharmacokinetics may be altered, but no dose recommendations are available. Sulfinpyrazone is not recommended for use in pregnancy.
Increased renal clearance and volume of distribution in pregnancy may reduce probenecid half-life; dose adjustment based on therapeutic response and serum uric acid levels is recommended. No specific dosing guidelines; clinical judgment advised.
Sulfinpyrazone is a uricosuric agent used for chronic gout; avoid in acute gout attack. Monitor renal function and uric acid levels. Contraindicated in peptic ulcer disease due to GI irritation. May potentiate warfarin and sulfonylureas; adjust doses accordingly.
BENEMID (probenecid) inhibits renal tubular secretion of penicillins and cephalosporins, increasing their serum levels. Use with caution in patients with G6PD deficiency due to risk of hemolytic anemia. Avoid in patients with blood dyscrasias or peptic ulcer disease. Ensure adequate hydration to prevent urate nephropathy during gout therapy.
Take with food or milk to reduce GI upset.,Drink plenty of fluids (at least 2-3 liters daily) to prevent kidney stones.,Avoid aspirin and other salicylates as they reduce effectiveness.,Report any signs of bleeding, bruising, or abdominal pain immediately.,Do not stop abruptly; discuss with your doctor.
Take with food or milk to reduce gastrointestinal upset.,Drink plenty of fluids (at least 2 liters daily) to prevent kidney stones.,Do not take with aspirin or other salicylates as they may reduce effectiveness.,This medication may increase the effects of other drugs like penicillins and methotrexate.,Report any signs of allergic reaction, severe skin rash, or joint pain immediately.
"Tolvaptan, a vasopressin V2 receptor antagonist, may increase the serum concentration of sulfinpyrazone, a uricosuric agent, primarily through inhibition of OATP1B1/1B3 and possibly other hepatic uptake transporters. This interaction can lead to elevated sulfinpyrazone levels, raising the risk of adverse effects such as renal impairment or hypersensitivity reactions. Careful monitoring and dose adjustment of sulfinpyrazone are recommended when coadministered with tolvaptan."
"Rifaximin, a non-systemic antibiotic primarily acting in the gastrointestinal tract, is a substrate of P-glycoprotein (P-gp) and may induce P-gp expression. Sulfinpyrazone, a uricosuric agent and P-gp inhibitor, can increase the bioavailability and systemic exposure of rifaximin by inhibiting its efflux transport. This interaction may lead to elevated rifaximin serum concentrations, potentially increasing the risk of systemic adverse effects such as Clostridioides difficile infection or hepatic impairment, though clinical data on this specific combination are limited."
"Colchicine may increase the serum concentration of sulfinpyrazone, a uricosuric agent, potentially enhancing its therapeutic effect and risk of toxicity. This interaction is likely mediated by colchicine's inhibition of hepatic cytochrome P450 enzymes and/or interference with biliary excretion of sulfinpyrazone. Clinically, this could lead to elevated sulfinpyrazone levels, increasing the risk of adverse effects such as gastrointestinal disturbances, hypersensitivity reactions, or renal impairment."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SULFINPYRAZONE vs BENEMID, answered by our medical review team.
SULFINPYRAZONE is a Uricosuric that works by Competitive inhibitor of tubular organic anion transport, increasing uric acid excretion; also inhibits platelet aggregation.. BENEMID is a Uricosuric Agent that works by Competitive inhibitor of renal tubular secretion of organic acids (urate, penicillin, other drugs), enhancing urate excretion and reducing serum uric acid levels. Also inhibits renal transport of weak organic acids.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SULFINPYRAZONE and BENEMID depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SULFINPYRAZONE is: 100-200 mg orally twice daily, initially, then increase to 200-400 mg twice daily.. The standard adult dose of BENEMID is: 250 mg orally twice daily for 1 week, then 500 mg orally twice daily; maximum 2 g/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SULFINPYRAZONE and BENEMID in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SULFINPYRAZONE is classified as Category A/B. Sulfinpyrazone is contraindicated in pregnancy. Animal studies have shown teratogenic effects, and there are no adequate human studies. First trimester exposure may carry a risk of. BENEMID is classified as Category C. FDA Pregnancy Category D for second and third trimesters due to risk of neonatal hemolysis and jaundice from sulfonamide component; first trimester use associated with possible neu. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.